ArticlePloS one2022

Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation.

Sylvie Perreault et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.